Traders News Issues Research, Growing Companies with New Product Development Catalysts

New York, NY -- April 24, 2018 -- InvestorsHub NewsWire -- Max Sound Corporation (OTCBB: MAXD), “MAX-D is a Proprietary Audio Process that restores lost compressed harmonics & brings high definition sound to digital media. MAXD is currently in negotiations with one of the world’s leading Gaming Companies to distribute their line-up of award winning games with MAXD HD Audio. MAXD is poised to be at the forefront of servicing the digital coin industry by using its successful HD Audio App while partnering and/or developing other Apps in lifestyle, talent discovery, mindfulness and other social experiences as a means to “airdrop” issuer’s coins in free promotional giveaways to consumers.

Get our research reports and our low float feature report with no obligation READ MORE
Copy and paste to browser may be required – https://secure.blueoctane.net/forms/KBZ53HQCKA06

Progressive Care, Inc. (OTCQB: RXMD) through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization. On April 13, 2018 PharmCo, LLC announced increased prescriptions filled and revenue for March 2018. PharmCo, LLC filled over 22,800 prescriptions during the month of March, generating nearly $1.9 million in net revenues. Prescriptions filled, and revenues increased by 20% and 18% respectively compared to the same month last year.

Advaxis, Inc. (NASDAQ: ADXS), a clinical and late stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology-based immunotherapies. Their Lm Technology, A Proprietary Antigen Delivery Platform that Activates the Immune System, naturally represents an advancement in the field of immunotherapy, as its comprehensive immune stimulation and priming redirects a “pathogen-like” response against cancers.

Get our research reports with no obligation and our low float feature report READ MORE
Copy and paste to browser may be required – https://secure.blueoctane.net/forms/KBZ53HQCKA06

Rising India, Inc., (OTCPK: RSII), operating as Rising Biosciences, Inc.is a research and development company focusing on oral and topical cannabis and non-cannabis-based pharmaceuticals. Rising Biosciences will also be rolling out its RBS0238 CLINICAL PEPTIDE SERUM (scar serum) in Q2. The company expects their product line will be on sale, available for national distribution, in late April/early May. The serum produces visible results with an effective ingredient base and delivery system.

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS LLC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.